Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 862 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
FOCAL+, VR-FOCAL+
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
16 Years to 19 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
ADHD
Interventions
Lisdexamfetamine dimesylate (LDX), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Rolling Hills Estates, California • South Miami, Florida • Overland Park, Kansas + 1 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
Interventions
MG01CI (1400 mg), placebo
Drug
Lead sponsor
Alcobra Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Gainesville, Florida • South Miami, Florida • Libertyville, Illinois + 15 more
Completed No phase listed Observational Accepts healthy volunteers

Genetic, Brain Structure, and Environmental Effects on ADHD

NCT01721720
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
3 Years and older
Enrollment
1,091 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine Extended Release, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain Dopamine Function in Adults With ADHD

NCT00580814
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Experimental: methylphenidate treatment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Irvine, California
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 25 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
ADHD
Interventions
OROS methylphenidate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
6 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Child Behavior Disorders, Attention Deficit Disorder With Hyperactivity, Disorders of Excessive Somnolence
Interventions
CPAP treatment, No CPAP treatment
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Terminated Phase 2 Interventional Accepts healthy volunteers

Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial

NCT02156089
Conditions
Attention Deficit Disorder, Attention Deficit Hyerpactivity Disorder
Interventions
Highly unsaturated omega-3 fatty acids
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
ADHD
Interventions
atomoxetine (Strattera)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
Interventions
CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Recruiting Not applicable Interventional Accepts healthy volunteers

Executive Function Training for Children and Adolescents

NCT07147894
Conditions
Cognitive Change
Interventions
Nongamified N-back training, Gamified N-back training, Multiple Domain Training, Coaching Session
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
12 Years to 17 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study

NCT03252522
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants, Placebo
Combination Product · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 12 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Conditions
Cannabis Use Disorder, Attention-deficit/Hyperactivity Disorder
Interventions
Adderall-XR, Matched placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
ADHD
Interventions
CLS-R
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years to 11 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
San Francisco, California
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LDX Treatment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Orange, California • Miami, Florida + 13 more
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 2 Interventional Results available

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Conditions
ADHD
Interventions
ADHD Therapy
Device
Lead sponsor
Lumos Labs, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Jacksonville, Florida • Lakeland, Florida • Rochester Hills, Michigan + 2 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate-OROS, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
9 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas